GIST Specialist for Malibu, CA
Gastrointestinal stromal tumors spread to two places: the liver, and the lining of the abdominal cavity. The second is harder to see, harder to operate on, and more often mismanaged. Joshua Ellenhorn, MD, FACS assesses it honestly.
- Assessment of peritoneal disease, including when surgery cannot help
- Clinical Professor of Surgery, Cedars-Sinai Medical Center
- Remote review of imaging before you drive the coast
- Works alongside your medical oncologist
Why Peritoneal Disease Is Different From Liver Disease
A liver metastasis is a discrete object. It sits in a specific segment, it can be measured on successive scans, and if a small number of them are all that remains after a good response to treatment, they can be removed or ablated with a reasonable expectation of clearing them.
Peritoneal disease is not like that. The peritoneum is a large continuous membrane lining the entire abdominal cavity and draping over the organs within it. GIST seeds onto that surface as nodules, frequently many of them, frequently small, distributed across an area no operation can systematically clear. And because CT is much better at finding one two centimetre mass in the liver than several five millimetre nodules on a folded membrane, small volume peritoneal disease is often simply invisible.
That has two consequences worth stating plainly. A clean scan does not entirely exclude peritoneal disease, particularly in a patient whose tumor ruptured. And the surgical ambition has to be different: not clearance, but selective removal of a limited number of deposits in a patient whose disease is otherwise well controlled.
The corollary is that targeted therapy carries more of the weight here than it does for liver disease. A tablet reaches every deposit simultaneously, including the ones nobody can see, which is precisely what distributed disease requires and precisely what an operation cannot deliver.
Liver Versus Peritoneal Spread
Both are treated with targeted therapy first. Where they differ is in what surgery can realistically add.
| Liver metastases | Peritoneal deposits | |
|---|---|---|
| Detectability on CT | Good. Discrete, measurable, comparable between scans | Poor for small nodules. Distributed over a large folded surface |
| Typical pattern | A limited number of defined masses | Often numerous small nodules across several surfaces |
| Usual route of spread | Through the bloodstream | Seeding, most often following tumor rupture |
| Surgical options | Resection or ablation, with a reasonable chance of clearing limited disease | Selective removal of a few discrete deposits. Systematic clearance rarely achievable |
| Role of targeted therapy | Leads treatment, with surgery consolidating | Leads treatment more decisively, because it reaches deposits imaging cannot find |
| Monitoring | Serial CT with density assessment against prior studies | Imaging plus clinical assessment, and laparoscopy where direct inspection is needed |
Cytoreductive surgery with heated intraperitoneal chemotherapy has a role in some peritoneal cancers. It is not standard treatment for GIST, because GIST responds to targeted tablets rather than to the conventional chemotherapy that technique delivers.
Why Rupture and Peritoneal Disease Are Linked
GIST arises from the interstitial cells of Cajal, pacemaker cells inside the wall of the digestive tract, and it grows outward within a capsule. While that capsule is intact the disease is contained, which is why complete removal of an unruptured tumor is usually curative.
When the capsule is breached, cells enter the abdominal cavity and settle on the peritoneal surfaces. That is the direct route from a contained tumor to distributed disease, and it is why rupture reclassifies a tumor as high risk regardless of its size. It can happen spontaneously before any operation, or during surgery through handling the tumor, dividing it, or removing it in fragments.
It also explains the surveillance emphasis after a ruptured tumor. Since microscopic peritoneal disease is presumed present and cannot be imaged, targeted therapy is frequently continued indefinitely rather than for a fixed three year course, and follow up is closer and longer than it would otherwise be.
What Is Actually Done
Peritoneal GIST is treatable. What it is not is a surgical problem in the way liver disease can be.
Targeted Therapy
Imatinib and its successors act on every deposit at once, seen and unseen. For distributed disease this is not a holding measure, it is the principal treatment, and many patients are controlled for years.
Resection of Discrete Deposits
A limited number of defined nodules, in a patient whose disease is otherwise controlled, can be removed. Particularly where one is growing while the rest stay stable, which suggests a resistant clone in that specific site.
Diagnostic Laparoscopy
Imaging cannot reliably exclude small volume peritoneal disease. Direct inspection through small incisions can, and it occasionally changes the plan substantially in either direction.
The Operations, on Record
Recordings of real GIST resections narrated by the surgeon who performed them. Watch how the tumor is handled, because capsule integrity is what determines whether peritoneal disease ever becomes your problem.
Laparoscopic Resection of a Gastric GIST
A gastric GIST removed through small incisions with the capsule kept intact throughout.
Gastric GIST Resection: A Simplified Approach
A refined approach that shortens operating time without compromising specimen handling.
Robotic Resection of a Duodenal GIST
Duodenal GIST removed robotically with the pancreas and bile duct preserved.
The Best Time to Address This Is Before Surgery
Peritoneal disease most often follows a ruptured capsule. Asking how the tumor will be removed, and whether it comes out whole and in a bag, matters more than any subsequent treatment for the consequences.
Certifications and Appointments
Two American Board of Surgery certifications, a Cedars-Sinai teaching appointment, and membership of the societies that publish the guidelines for advanced GIST.
- American Board of Surgery, certified in General Surgery
- American Board of Surgery, certified in Colorectal Surgery
- California State Medical License
- Florida State Medical License
Joshua Ellenhorn, MD, FACS
Dr. Ellenhorn is a surgical oncologist and Clinical Professor of Surgery at Cedars-Sinai Medical Center, and a collaborative member of the Samuel Oschin Comprehensive Cancer Institute.
Peritoneal GIST is a subject where a surgeon has to be willing to say that surgery is not the answer. There is real commercial and psychological pressure toward offering an operation to a patient with visible disease, and there are techniques used for other peritoneal cancers that can be presented as applicable here without good evidence. Being straightforward about the limits of what an operation achieves in diffuse disease, and directing the weight of treatment toward the medication instead, is the honest position even though it is the less impressive one.
He is certified by the American Board of Surgery in General Surgery and in Colorectal Surgery, a Fellow of the American College of Surgeons, and a member of the Society of Surgical Oncology and the American Society of Clinical Oncology. He practises with the Surgery Group of Los Angeles.
Questions Worth Asking
These help establish what is actually known about your disease and what treatment can realistically achieve.
- Was tumor rupture documented at my original surgery?
- How extensive is the peritoneal disease on imaging?
- Could there be disease the scan is not showing?
- Am I responding to the current drug, assessed on density as well as size?
- Is any deposit growing while the others stay stable?
- Would removing a specific deposit extend the drug I am on?
- Is diagnostic laparoscopy worth considering?
- Is heated intraperitoneal chemotherapy supported by evidence in GIST?
What Patients Say
Reviews left by patients treated by Dr. Ellenhorn at the Surgery Group of Los Angeles.
★★★★★Very kind stuff, great service. Dr Joshua Ellenhorn is a very calm doctor who takes time with his patient.
Anita Lukacevic
★★★★★I was very pleased with the office staff, they were always very pleasant and helpful. I was very impressed with Dr. Ellenhorn as well. He was very friendly and addressed all my concerns regarding my surgery and aftercare and follow up.
Terry Jackson
From Malibu
Pacific Coast Highway to Sunset and east is the usual route, or down to the 10 and north on La Cienega if the highway is moving. Depending on where in Malibu you start and the state of PCH, allow forty five minutes to an hour, and considerably more on a summer weekend.
Given that distance, remote review is usually the sensible first step. Send imaging and pathology, get a specific opinion on whether an in person consultation would change anything, and travel only if it would. For the questions on this page much of the assessment is imaging based, which lends itself well to that.
When you do come in, the office is in the medical plaza attached to Cedars-Sinai Medical Center, so consultation, imaging review and any procedure happen in one building rather than across several trips down the coast.
8635 W 3rd St, Suite 880W
Los Angeles, CA 90048
Monday to Saturday, 11:00am to 8:00pm
Closed Sunday
Frequently Asked Questions
What does peritoneal disease mean?
Why is peritoneal disease harder to detect?
Is peritoneal spread the same as rupture?
Can peritoneal disease be operated on?
What about heated chemotherapy into the abdomen?
So what is the main treatment?
How is peritoneal disease monitored if scans miss it?
How far is your office from Malibu?
Peritoneal Disease Is Treatable, But Not Mainly With Surgery.
Targeted therapy reaches deposits imaging cannot find, and surgery is selective rather than curative here. Be wary of anyone offering an operation as the primary answer.
